Study S002381

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01536665
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 45
Start: 2012-02
Primary completion: 2012-08
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1123-9882; EUDRACT_NUMBER:2011-004240-22

Registered primary outcomes

Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ) [At week 4]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015060	Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus. Mader JK, Clinical pharmacokinetics	2016	Randomized trial	PMID 27282158 DOI	cites ClinicalTrials.gov:NCT01536665; registry reference RESULT:27282158
R0016408	Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Pieber TR, Diabetes, obesity & metabolism	2015	Randomized trial	PMID 25855340 DOI	cites ClinicalTrials.gov:NCT01536665; registry reference RESULT:25855340
R0049328	Liraglutide is a Safe and Beneficial Adjunct to Insulin in Glycemic Control in Type 1 Diabetes Brian D. Hoyle, MD Conference Express	2013	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01536665